Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore GSK
Core profile pages, annual revenue records, and related research hubs for this company.
Compare market positioning with top industry peers
Explore GSK
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
GBP 32.7B
Market Cap
$82.1B
Net Income
$5.7B
Employees
70,200
GSK is operating as a focused, standalone pure-play biopharma company following the successful spin-off of its consumer healthcare division. Under CEO Emma Walmsley, the British pharmaceutical giant generated exactly $36.8 billion in revenue and maintains a $82.1 billion market cap with exactly 70200 employees. The financial narrative in 2026 is entirely defined by its dominance in vaccines (specifically Shingrix and Arexvy) and aggressive investments in complex infectious disease pipelines, defying activist investor pressure that previously demanded a total break-up of the company.
Revenue Trend Analysis
YoY Change
+4.1%
2-Year CAGR
+3.8%
Peak Year
2025
Trend
Consistent Growth
GSK plc has reported revenue across 3 fiscal years, compounding at +3.8% annually over 2 years. The most recent year saw a 4.1% increase versus the prior year. Revenue peaked in 2025 at $32.7B. Out of 2 reported periods, 2 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $32.7B | $5.7B | +4.1% |
| FY2024 | $31.4B | — | +3.5% |
| FY2023 | $30.3B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
GSK plc reported approximately $36.8B in fiscal year 2025 with a team of 70,200 employees worldwide.
GSK plc strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Pharmaceuticals & Biotechnology is driven by steady cash generation and pricing power, enabling GSK plc to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "GSK plc Revenue & Financials." CorpDigest, https://corpdigest.com/company/gsk/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>GSK plc reported $33B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/gsk/financials" target="_blank" rel="noopener">CorpDigest — GSK plc financials</a></div>